サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1696295

局所進行膵臓がんの世界市場：2025年～2033年

Global Locally Advanced Pancreatic Cancer Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
局所進行膵臓がんの世界市場：2025年～2033年
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の局所進行膵がんの市場規模は、2024年に13億1,000万米ドルに達し、2033年には23億8,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは7.0％と見込まれています。

局所進行膵がんとは、腫瘍が膵臓とその周辺に限局しているが肝臓、肺、遠隔リンパ節などの遠隔臓器には転移していない膵がんの病期を指します。この段階では、がんが局所的に増殖し、近くの血管や神経、構造物を巻き込んでいる可能性があり、外科的切除が困難となります。

がんが十二指腸、胆管、脾臓、太い血管（上腸間膜動脈や門脈など）などの隣接する構造物に及ぶこともあり、手術のリスクが高くなったり、手術が不可能になったりします。がんが局所に限局しているにもかかわらず、この段階では「切除不能」とみなされることが多いです。これは、腫瘍が近傍の血管や神経に浸潤しているため、重篤な合併症を引き起こさない限り完全な外科的切除が不可能だからです。

局所進行膵がんの治療には通常、化学療法、放射線療法、場合によっては標的療法や免疫療法が併用されます。治療後に腫瘍が著しく縮小し、切除可能となった場合には、まれに手術が選択されることもあります。

先進治療に対する需要の高まりが、局所進行膵がん市場の成長を大きく後押ししています。

局所進行膵がんは進行した段階で診断されることが多く、従来の化学療法では限界があるため、より正確かつ効果的に疾患を治療できる革新的な治療法が求められています。全生存期間を改善するために、進行中の臨床試験に患者を登録するのは一般的な方法です。

現在、いくつかの臨床試験が進行中であり、局所進行膵がんに対する多くの治療選択肢を評価しており、有望な結果を示しています。例えば、ニボルマブ（オプジーボ）やペムブロリズマブ（キイトルーダ）のような免疫チェックポイント阻害剤は、局所進行膵がんの治療薬としての可能性が検証されています。これらの治療薬は、がん細胞を認識して攻撃する免疫系を増強することで効果を発揮し、膵臓がんに対する臨床試験で有望視されています。

さらに2024年12月、Novocureは、主要な第3相PANOVA-3試験が主要評価項目を達成し、全生存期間中央値（mOS）が対照群と比較して統計学的に有意に改善したことを発表しました。PANOVA-3試験では、切除不能な局所進行膵腺がんに対する一次治療として、ゲムシタビンおよびナブパクリタキセルと併用したTumor Treating Fields（TTFields）療法の使用が評価されました。

さらに、中国のPeking Union Medical College Hospitalでは現在、局所進行膵がんの治療に対するニモツズマブとFOLFIRINOXの併用療法の安全性と有効性を評価しています。この研究は、全生存率、無増悪生存期間、客観的奏効率などのパラメータを評価する第II相試験です。

局所進行膵がん患者の全生存期間を延長し、QOLを改善する可能性があるため、これらの先進治療に対する需要は高まっています。このような先進療法は現在臨床開発中であり、局所進行膵がん治療において有望な結果を示しています。

治療法の進歩にもかかわらず、このタイプの膵がんは、その侵攻性、診断の後期化、多くの治療法に対する耐性のため、依然として治療が最も困難ながんのひとつです。しかし、化学療法はこの疾患に対する主要な治療選択肢の一つであり、その有効性は患者集団の大部分において限定的であり、再発が予想されます。

例えば、LAPCの標準治療にはFOLFIRINOXゲムシタビン、ナブパクリタキセルなどがよく用いられます。このレジメンは単剤療法に比べ生存率を改善するが、それでも一部の患者にしか有効でなく、生存率の延長はわずかです。

さらに、ニボルマブやペムブロリズマブのような免疫チェックポイント阻害剤も有望と考えられていますが、その有効性を評価するため、また現在の治療法と比較して全生存率を延長できるかどうかを評価するためには、さらなる試験を実施する必要があります。放射線療法はLAPCに対して化学療法と併用されることが多いですが、腫瘍が重要臓器に近接していることや放射線に対する抵抗性などの要因により、その有効性は制限されます。

当レポートでは、世界の局所進行膵臓がん市場について調査し、市場の概要とともに、治療法別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 目次

第2章 市場のイントロダクションと範囲

第3章 エグゼクティブの洞察と重要なポイント

第4章 市場のハイライトと戦略的ポイント

  • 主な動向と将来の予測

第5章 治療法別概要

  • エンドユーザー別
  • 地域別

第6章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第7章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • 疫学分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第8章 局所進行膵臓がん市場、治療法別

  • 化学療法
    • ゲムシタビン
    • フォルフィリノックス
    • ナブパクリタキセル
    • シスプラチン
    • その他
  • 免疫療法
  • 標的療法
    • ラロトレクチニブ
    • エヌトレクチニブ
  • 放射線治療
  • 手術
    • ホイップル手術
    • 膵臓全摘出術
    • 膵体尾部切除術

第9章 局所進行膵臓がん市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 研究機関

第10章 局所進行膵臓がん市場、地域別市場分析と成長機会

第11章 イントロダクション

  • 北米
    • 地域特有の主な動向
      • 米国
      • カナダ
  • 欧州
    • 地域特有の主な動向
      • ドイツ
      • 英国
      • フランス
      • スペイン
      • イタリア
      • その他
  • ラテンアメリカ
    • 地域特有の主な動向
      • メキシコ
      • ブラジル
      • アルゼンチン
      • その他
  • アジア太平洋
    • 地域特有の主な動向
      • 中国
      • インド
      • 日本
      • 韓国
      • その他
  • 中東・アフリカ
    • 地域特有の主な動向

第12章 競合情勢と市場ポジショニング

第13章 競合状況の概要と主要市場参入企業

  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第14章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオ

第15章 財務概要

  • 企業収益
    • 地域別収益分配
    • 主な発展
    • SWOT分析
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Merus N.V.
  • Pfizer Inc.
  • Fresenius Kabi AG
  • BRISTOL-MYERS SQUIBB COMPANY
  • CHEPLAPHARM Arzneimittel GmbH
  • Bayer AG

第16章 仮定と調査手法

第17章 付録

目次
Product Code: PH6764

The global locally advanced pancreatic cancer market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.38 billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033.

Locally advanced pancreatic cancer refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and the surrounding areas but has not spread to distant organs like the liver, lungs, or distant lymph nodes. In this stage, the cancer has grown locally and may involve nearby blood vessels, nerves or structures, making it difficult to remove surgically.

The cancer may extend to adjacent structures such as the duodenum, bile ducts, spleen and large blood vessels (such as the superior mesenteric artery or the portal vein), which can make surgery risky or infeasible. Despite the cancer being confined to the local area, it is often considered "unresectable" at this stage because the tumor's involvement with nearby blood vessels or nerves means complete surgical removal is not possible without risking severe complications.

The management of locally advanced pancreatic cancer usually involves a combination of chemotherapy, radiation therapy and in some cases, targeted therapy or immunotherapy. Surgery might be an option in rare cases if the tumor shrinks significantly after treatment, allowing it to become resectable.

Market Dynamics: Drivers & Restraints

The rising demand for advanced therapies is significantly driving the locally advanced pancreatic cancer market growth

Locally advanced pancreatic cancer is often diagnosed at an advanced stage, and traditional chemotherapy treatments have limitations, prompting the need for innovative therapies that can target the disease more precisely and effectively. It is a general practice to enroll patients in ongoing clinical trials to improve their overall survival.

Several clinical trials are currently ongoing which are evaluating a plethora of treatment options for locally advanced pancreatic cancer, and are showing promising results. For instance, immune checkpoint inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda) are being tested for their potential to treat locally advanced pancreatic cancer. These therapies work by boosting the immune system to recognize and attack cancer cells, showing promise in clinical trials for pancreatic cancer.

Additionally, in December 2024, Novocure announced that the pivotal Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

Moreover, Peking Union Medical College Hospital in China is currently evaluating the safety and efficacy of Nimotuzumab in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer. The study is in Phase II trials evaluating parameters such as overall survival rate, progression free survival, objective response rate etc.

The demand for these advanced therapies is growing as they offer the potential for longer overall survival and better quality of life for locally advanced pancreatic cancer patients. There are several such advanced therapies currently in clinical development and are showing promising results in locally advanced pancreatic cancer treatment.

Limited efficacy of current therapies hampering the market growth

Despite advances in treatment, this type of pancreatic cancer remains one of the most difficult cancers to treat due to its aggressive nature, late-stage diagnosis and resistance to many therapies. However, chemotherapy stands as a major therapy option for the condition, whose efficacy is limited in the majority of the patient population, and a recurrence is expected in most of them.

For instance, the standard treatment for LAPC often includes FOLFIRINOX gemcitabine, nab-paclitaxel, etc. While this regimen improves survival compared to monotherapies, it is still only effective for a portion of patients, prolonging the survival rate to a mere extent.

Additionally, immune checkpoint inhibitors, like nivolumab and pembrolizumab were considered promising but, further trials have to be conducted to evaluate their efficacy, and if they can prolong the overall survival rate as compared with the current therapies. Radiation therapy is often used in combination with chemotherapy for LAPC, but its effectiveness is limited by factors such as the tumor's proximity to vital organs and its resistance to radiation.

Segment Analysis

The global locally advanced pancreatic cancer market is segmented based on therapy, end-user and region.

Therapy:

The chemotherapy segment is expected to dominate the locally advanced pancreatic cancer market with the highest market share

Chemotherapy is a drug treatment that essentially kills cells, especially the fast-growing cancer cells, and inhibits their rapid growth and multiplication. Various chemotherapy drugs could be used either alone or in combination to treat different types of cancers. The most common chemotherapy drugs used in locally advanced pancreatic cancer are Gemcitabine, Folfirinox, Nab-Paclitaxel, Cisplatin and others.

At present, chemotherapy stands as a major therapeutic option for locally advanced pancreatic cancer, with many health governing bodies recommending them as first-line treatment options in LAPC. These drugs shrink the tumor size making it convenient for surgical resection.

As per the National Comprehensive Cancer Network (NCCN) guidelines, the standard of care for LAPC includes FOLFIRINOX or modified FOLFIRINOX, or Gemcitabine + nab-paclitaxel. According to the European Society for Medical Oncology (ESMO) guidelines, The first-line therapy for LAPC includes either FOLFIRINOX or Gemcitabine + nab-paclitaxel.

Additionally, according to the Japan Pancreas Society Practice Guidelines 2022, the first-line treatment for LAPC includes chemotherapy with FOLFIRINOX or Gemcitabine + nab-paclitaxel, or Gemcitabine monotherapy. Chemotherapy is practiced across the world as the first line of care, due to its efficacy as compared to other treatment options, and its capability to improve the overall survival rate in LAPC patients.

Geographical Analysis

North America is expected to hold a significant position in the global locally advanced pancreatic cancer market with the highest market share

The locally advanced pancreatic cancer market in the North America region is expected to grow owing to the strong presence of major market players, the rising prevalence of pancreatic cancers, increasing research activities, rising awareness about cancer, rising clinical studies and well-established healthcare infrastructure are the factors expected to drive the market in the region.

The prevalence of pancreatic cancer in the United States is continuously rising which further increases the demand for treatment options. Factors such as aging populations, lifestyle changes and the prevalence of risk factors like obesity and smoking are driving the demand for improved treatments. For instance, the American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are that about 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer and about 51,750 people (27,270 men and 24,480 women) will die of pancreatic cancer.

Moreover, in November 2024, Northwell Health Cancer Institute joined RenovoRx's Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer. The trial evaluates RenovoRx's TAMP therapy platform, comparing intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath system to standard intravenous chemotherapy. The study aims to complete enrollment in the first half of 2025.

Competitive Landscape

Top companies in the locally advanced pancreatic cancer market includes F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, Merus N.V., Pfizer Inc., Fresenius Kabi AG, BRISTOL-MYERS SQUIBB COMPANY, CHEPLAPHARM Arzneimittel GmbH and Bayer AG among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global locally advanced pancreatic cancer market report delivers a detailed analysis with 54 key tables, more than 44 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Table of Contents

2. Market Introduction and Scope

  • 2.1. Objectives of the Report
  • 2.2. Report Coverage & Definitions
  • 2.3. Report Scope

3. Executive Insights and Key Takeaways

4. Market Highlights and Strategic Takeaways

  • 4.1. Key Trends and Future Projections

5. Snippet by Therapy

  • 5.1. Snippet by End-User
  • 5.2. Snippet by Region

6. Dynamics

  • 6.1. Impacting Factors
    • 6.1.1. Drivers
      • 6.1.1.1. Rising Demand for Advanced Therapies
      • 6.1.1.2. Rising Adoption of Combination Therapies
    • 6.1.2. Restraints
      • 6.1.2.1. Limited Efficacy of Current Therapies
      • 6.1.2.2. High Cost of Treatment for Locally Advanced Pancreatic Cancer
    • 6.1.3. Opportunity
      • 6.1.3.1. AI and Big Data Analytics in Cancer Treatment
    • 6.1.4. Impact Analysis

7. Strategic Insights and Industry Outlook

  • 7.1. Market Leaders and Pioneers
    • 7.1.1. Emerging Pioneers and Prominent Players
    • 7.1.2. Established Leaders with Largest Marketing Brand
    • 7.1.3. Market Leaders with Established Product
  • 7.2. Latest Developments and Breakthroughs
  • 7.3. Regulatory and Reimbursement Landscape
    • 7.3.1. North America
    • 7.3.2. Europe
    • 7.3.3. Asia Pacific
    • 7.3.4. Latin America
    • 7.3.5. Middle East & Africa
  • 7.4. Porter's Five Force Analysis
  • 7.5. Epidemiology Analysis
  • 7.6. Supply Chain Analysis
  • 7.7. Patent Analysis
  • 7.8. SWOT Analysis
  • 7.9. Unmet Needs and Gaps
  • 7.10. Recommended Strategies for Market Entry and Expansion
  • 7.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 7.12. Pricing Analysis and Price Dynamics
  • 7.13. Key Opinion Leaders

8. Locally Advanced Pancreatic Cancer Market, By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.1.2. Market Attractiveness Index, By Therapy
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Gemcitabine
    • 8.2.4. Folfirinox
    • 8.2.5. Nab-Paclitaxel
    • 8.2.6. Cisplatin
    • 8.2.7. Others
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy
    • 8.4.1. Larotrectinib
    • 8.4.2. Entrectinib
  • 8.5. Radiation Therapy
  • 8.6. Surgery
    • 8.6.1. Whipple Procedure
    • 8.6.2. Total Pancreatectomy
    • 8.6.3. Distal Pancreatectomy

9. Locally Advanced Pancreatic Cancer Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Research Institutions

10. Locally Advanced Pancreatic Cancer Market, By Regional Market Analysis and Growth Opportunities

11. Introduction

  • 11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.1. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.5.1. U.S.
      • 11.2.5.2. Canada
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. UK
      • 11.3.5.3. France
      • 11.3.5.4. Spain
      • 11.3.5.5. Italy
      • 11.3.5.6. Rest of Europe
  • 11.4. Latin America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Mexico
      • 11.4.5.2. Brazil
      • 11.4.5.3. Argentina
      • 11.4.5.4. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. South Korea
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape and Market Positioning

13. Competitive Overview and Key Market Players

  • 13.1. Market Share Analysis and Positioning Matrix
  • 13.2. Strategic Partnerships, Mergers & Acquisitions
  • 13.3. Key Developments in Product Portfolios and Innovations
  • 13.4. Company Benchmarking

14. Company Profiles

  • 14.1. F. Hoffmann-La Roche Ltd.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio
      • 14.1.2.1. Product Description
      • 14.1.2.2. Product Key Performance Indicators (KPIs)
      • 14.1.2.3. Historic and Forecasted Product Sales
      • 14.1.2.4. Product Sales Volume

15. Financial Overview

  • 15.1. Company Revenue
    • 15.1.1. Geographical Revenue Shares
      • 15.1.1.1. Revenue Forecasts
    • 15.1.2. Key Developments
      • 15.1.2.1. Mergers & Acquisitions
      • 15.1.2.2. Key Product Development Activities
      • 15.1.2.3. Regulatory Approvals, etc.
    • 15.1.3. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Teva Pharmaceutical Industries Ltd
  • 15.5. Merus N.V.
  • 15.6. Pfizer Inc.
  • 15.7. Fresenius Kabi AG
  • 15.8. BRISTOL-MYERS SQUIBB COMPANY
  • 15.9. CHEPLAPHARM Arzneimittel GmbH
  • 15.10. Bayer AG(LIST NOT EXHAUSTIVE )

16. Assumption and Research Methodology

  • 16.1. Data Collection Methods
  • 16.2. Data Triangulation
  • 16.3. Forecasting Techniques
  • 16.4. Data Verification and Validation

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us